Trial Profile
Interventional, Randomized, Double-blind, Placebo-controlled, Active-reference (Fluoxetine), Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 7 to 11 Years, With Major Depressive Disorder (MDD)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Dec 2022
Price :
$35
*
At a glance
- Drugs Vortioxetine (Primary) ; Fluoxetine
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Sponsors Lundbeck A/S
- 03 Feb 2022 Status changed from active, no longer recruiting to completed.
- 24 Dec 2021 This trial has been completed in Bulgaria and Latvia, according to European Clinical Trials Database record
- 09 Dec 2021 Planned End Date changed from 30 Apr 2022 to 18 Feb 2022.